查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495948

視網膜電圖檢查市場 – 2024 年至 2029 年預測

Electroretinogram Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

視網膜電圖檢查市場預計將從2022年的605,024,000美元成長到2029年的1,098,966,000美元，複合年成長率為8.90%。

視網膜電圖測試是一種測量視網膜接收光線時發出的電脈衝的測試。視網膜電圖是一種眼科檢查，旨在發現視網膜正常功能的異常情況。眼睛後部的視網膜是眼睛中對光最敏感的細胞層。視網膜將光的訊息傳送到大腦。感光細胞由視桿細胞和視錐細胞組成，幫助我們看到光線，然後將其傳輸到其他視網膜細胞，例如雙極細胞。

人口老化更容易患青光眼和糖尿病視網膜病變等眼部疾病，對疾病早期診斷的需求不斷增加，以及持續的技術進步預計將推動市場成長。眼睛是人體最脆弱的器官，因此眼科檢查需要高度的精確度和準確度。這是市場成長的主要原因。此外，可支配收入的增加、對早期疾病診斷意識的提高以及政府對眼科研究和開發的資助的增加也推動了市場的成長。

監管支持和政府舉措

青光眼是損害眼睛視神經的疾病之一。當眼睛外表積聚一層液體，產生壓力，損害視神經時，就會發生這種疾病。還有一種疾病稱為滲出性脈絡膜病變。青光眼是一種可導致視力喪失並最終失明的疾病。據世界衛生組織 (WHO) 稱，青光眼被認為導致全球 450 萬人失明。據估計，美國有1,200萬人因青光眼失明，佔失明病例的9%至12%。 60 歲以上的人比年輕人更容易因青光眼而視力喪失。然而，如果及早發現並治療這種疾病，視力喪失是可以避免的。據認為，全球 40 歲以上人口中青光眼的年齡標準化盛行率為 3-5%。青光眼有兩種類型：開放性青光眼和隅角閉鎖性青光眼。最常見的青光眼類型稱為開放性青光眼，它與多種疾病有關，包括撒哈拉以南非洲人後裔、高眼壓、年齡較大、家族病史和高度近視等危險因子。

另一方面，年齡較大、處方箋以及東亞血統會增加隅角閉鎖性青光眼的風險。青光眼研究基金會估計，目前約有 300 萬美國人患有青光眼。美國國家眼科研究所預計，2030年，美國將有420萬人，增幅超過58%。非裔美國人和拉丁裔社區比白人社區更容易患青光眼，前者患青光眼的可能性是後者的六到八倍。

模式視網膜電圖測試（PERG）通常用作青光眼的診斷和治療工具，並被認為對青光眼的早期檢測有效。與其他常用於診斷和追蹤青光眼患者的測試相比，圖形視網膜電圖檢查 (PERG) 具有多種優點。具體來說，PERG 可以在疾病過程的早期檢測到功能異常，在某些情況下比任何其他測試早八年。 PERG 測試的高靈敏度可以及早發現異常情況，從而及時預防視網膜神經節細胞 (RGC) 死亡。由於 PERG 可以促進更好的檢測，由於與青光眼相關的失明病例數量不斷增加以及人們對該疾病的認知不斷增強，預計未來幾年市場將顯著成長。

固定 ERG 設備的需求增加

能夠治療大量患者並為廣泛的專業領域或僅一個專業領域提供服務的大型醫院是使用這些設備的理想地點。攜帶式EGR裝置比固定式EGR裝置更輕、更緊湊，使得攜帶式裝置更容易移動和運輸。然而，大多數攜帶式EGR 裝置的功能較少，且不如固定 EGR 裝置有效。它們在臨時診所或流動醫院中效果最好，這些診所或流動醫院在沒有永久性基礎設施的地方提供醫療服務。由於這兩種設備針對不同的消費者，因此它們對應的市場都很穩定並且呈現出健康的成長速度。

不斷增加的研究和藥物開發

目前眼科和視覺科學領域的研究舉措正在推動對先進診斷設備的需求，從而推動視網膜電圖檢查市場規模的擴大。 ERG 對於研究視網膜疾病和治療的研究人員來說是一個有用的工具。例如，2022 年 ERG 對暗適應的研究將揭示基本的生理過程。例如，2022 年 ERG 對暗適應的研究將揭示基本的生理過程。可以使用錐體驅動的暮光 a 波來追蹤錐體感光色素的恢復，這表明再生是速率限制的，而不是一階的。此外，梅奧診所目前正在進行一項研究，以評估光學相干斷層掃描 (OCT) 和光學相干斷層掃描血管造影術(OCTA) 對仰臥患者的成像能力。

北美地區將在預測期內快速成長

預計在預測期內，北美將佔據視網膜電圖檢查市場的主要佔有率。這一佔有率是由多種因素造成的，包括人口老化、眼科疾病發病率增加、新興國家核准和支出增加以及美國等已開發國家接受新產品的趨勢。例如，美國國家眼科研究所預測，到 2030 年，大約 430 萬美國人將患有青光眼，1,130 萬美國人將患有糖尿病視網膜病變。此外，根據同一資訊來源，每年視力喪失和眼部護理的費用估計約為 1.39 億美元。

主要市場進入

  • 2024年1月，科技公司Gentex Corp.宣布將收購視力增強科技公司eSight，以開發和製造下一代行動電子眼鏡產品，以幫助視覺障礙者。
  • 2023 年 6 月，私人公司DW Healthcare Partners 宣布已完成對LKC Technologies, Inc. 的投資，LKC Technologies, Inc. 是一家電生理測試設備製造商，用於治療青光眼和糖尿病視網膜病變等疾病。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章視網膜電圖市場：依技術分類

  • 介紹
  • 全場閃光 ERG (ffERG)
  • 模式 ERG (PERG)
  • 多焦點 ERG (mfERG)

第6章視網膜電圖市場：依產品

  • 介紹
  • 手持式
  • 桌上

第7章視網膜電圖市場：依應用分類

  • 介紹
  • 臨床診斷
  • 研究

第8章視網膜電圖檢查市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 有競爭力的儀表板

第10章 公司簡介

  • LKC Technologies
  • Eye Patient
  • ICR
  • WellFirst Health
  • Neurosoft
  • Roland Consult
  • Aetna
  • USF Health
  • Medico Electrodes
簡介目錄
Product Code: KSI061616012

The electroretinogram market is expected to grow at a CAGR of 8.90% from US$605.024 million in 2022 to US$1,098.966 million in 2029.

The term electroretinography refers to the study of the electrical impulses that the retina emits when exposed to light. To find any abnormalities in the retinas normal functioning an electroretinogram is one kind of eye that is conducted. The retina which is found at the back of the eye is the layer of cells in the eye that is most sensitive to light. The retina sends electrical messages to the brain bearing light data. Photoreceptors composed of rods and cones help us see lights before conveying it to other retinal cells like bipolar cells.

The geriatric population which is more likely to develop eye disorders like glaucoma and diabetic retinopathy as well as the growing demand for early disease diagnosis and ongoing technological advancements are anticipated to fuel market growth. Because the eyes are the most delicate organs in the body ophthalmic exam procedures require a high degree of accuracy and precision. The markets growth is primarily being driven by this. Furthermore, the market is growing due to rising levels of disposable income growing awareness of early disease diagnosis and increased government funding for ophthalmological R&D.

The imposition of regulatory support and government initiatives

One kind of illness that harms the optic nerve in the eye is glaucoma. This condition develops when a layer of fluid accumulates on the outer surface of the eye creating pressure that damages the optic nerves. Exudative choroidopathy is another name for it. One condition that can lead to visual loss and eventually blindness is glaucoma. According to the World Health Organization glaucoma is thought to be the cause of blindness in 4. 5 million people worldwide. It is estimated that glaucoma causes blindness in 120000 Americans accounting for 9-12% of all cases of blindness. Individuals over 60 are more likely than younger people to experience vision loss due to glaucoma. If the ailment is identified and treated early on however it is possible to avoid having one's vision compromised. Age-standardized prevalence estimates for glaucoma in people 40 years of age and older worldwide are thought to be between 3 and 5%. Two main subtypes of glaucoma can be distinguished: open-angle glaucoma and closed-angle glaucoma. The most common type of glaucoma is known as open-angle glaucoma which can be recognized by several risk factors such as being of African descent from sub-Saharan Africa having an elevated intraocular pressure being older having a positive family history and having high myopia.

By contrast having a strong prescription getting older and being of East Asian ethnicity increases the risk of developing closed-angle glaucoma. It is estimated by the Glaucoma Research Foundation that approximately 3 million Americans currently suffer from glaucoma. The National Eye Institute has provided projections indicating that by 2030 there could be up to 4 point 2 million people in the country-a rise of more than 58 percent. African American and Latino communities are also more likely to experience glaucoma than the Caucasian community the former are six to eight times more likely to be affected than the latter.

Pattern electroretinography or PERG is a commonly used diagnostic and therapeutic tool for glaucoma that is considered effective in identifying the disease early. Compared to other tests that are frequently used to diagnose and track glaucoma patients the Pattern Electroretinogram (PERG) offers a few advantages. Specifically, functional abnormalities can be found with PERG very early in the course of the disease in some cases this is possibly up to eight years earlier than with any of our other tests. Due to their sensitivity, PERG tests allow for the early detection of abnormalities and consequently the timely prevention of retinal ganglion cell (RGC) death. Since PERG can facilitate better detection it is expected that the market will experience significant growth in the coming years due to the rise in glaucoma-related blindness cases and increased awareness of the disease.

Increased demand for fixed ERG machines

Large hospitals with the ability to treat large numbers of patients and offer a wide range of specialities or just one are the ideal places for these devices to be used. Because the portable EGR machines are lighter and more compact than the fixed EGR machines the portable machines are easier to move and transport. However, the vast majority of portable devices are less feature-rich and less effective than their stationary counterparts. These work best in makeshift clinics and mobile hospitals that offer healthcare in places without permanent infrastructure. Since these two devices serve different kinds of consumers their corresponding markets are both stable and experiencing healthy rates of growth.

Rising research and drug development

Current ophthalmology and vision science research initiatives fuel the demand for sophisticated diagnostic instruments which in turn propels the size of the electroretinogram market. For researchers looking into retinal conditions and treatments, ERG is a useful tool. For instance ERG studies of dark adaptation in 2022 shed light on basic physiological processes. One can track cone photopigment recovery using the cone-driven dim-flash a-wave which shows that regeneration is rate-limited as opposed to first order. Additionally, the Mayo Clinic is now conducting studies to assess the imaging capabilities of optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) in supine patients.

North America is witnessing exponential growth during the forecast period

Over the course of the forecast period North America is anticipated to hold a sizable share of the electroretinogram market. This share can be attributed to several factors including an ageing population an increase in the incidence of eye problems a rise in approvals and RandD spending and a tendency in developed countries like the US to embrace novel products. By 2030 for example the National Eye Institute projects that approximately 4 Point 3 million Americans will suffer from glaucoma and 11 Point 3 million will have diabetic retinopathy. Furthermore, according to the same source, the annual cost of vision loss and eye care is estimated to be around $139 million.

Market key launches

  • In January 2024, Technology company Gentex Corp. announced, that it would acquire eSight, a provider of vision enhancement technologies, in order to create and produce the upcoming generation of mobile electronic eyewear, which will aid those who are visually impaired.
  • In June 2023, the healthcare-focused private equity firm DW Healthcare Partners announced that it had completed its investment in LKC Technologies, Inc., which makes electrophysiology testing devices that help with the diagnosis and treatment of conditions affecting the retina and optic nerve, including glaucoma and diabetic retinopathy.

Segmentation:

By Technology

  • Full-Field Flash ERG (ffERG)
  • Pattern ERG (PERG)
  • Multifocal ERG (mfERG)

By Product

  • Handheld
  • Tabletop

By Application

  • Clinical Diagnostic
  • Research

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. ELECTRORETINOGRAM MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Full-Field Flash ERG (ffERG)
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Pattern ERG (PERG)
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Multifocal ERG (mfERG)
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. ELECTRORETINOGRAM MARKET, BY PRODUCT

  • 6.1. Introduction
  • 6.2. Handheld
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Tabletop
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. ELECTRORETINOGRAM MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Clinical Diagnostics
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Research
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. ELECTRORETINOGRAM MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1.Market Trends and Opportunities
        • 8.2.4.1.2.Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1.Market Trends and Opportunities
        • 8.2.4.2.2.Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1.Market Trends and Opportunities
        • 8.2.4.3.2.Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Product
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1.Market Trends and Opportunities
        • 8.3.4.1.2.Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1.Market Trends and Opportunities
        • 8.3.4.2.2.Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1.Market Trends and Opportunities
        • 8.3.4.3.2.Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Product
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1.Market Trends and Opportunities
        • 8.4.4.1.2.Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1.Market Trends and Opportunities
        • 8.4.4.2.2.Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1.Market Trends and Opportunities
        • 8.4.4.3.2.Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1.Market Trends and Opportunities
        • 8.4.4.4.2.Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1.Market Trends and Opportunities
        • 8.4.4.5.2.Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Product
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1.Market Trends and Opportunities
        • 8.5.4.1.2.Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1.Market Trends and Opportunities
        • 8.5.4.2.2.Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1.Market Trends and Opportunities
        • 8.5.4.3.2.Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1.Market Trends and Opportunities
        • 8.5.4.4.2.Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Product
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1.Market Trends and Opportunities
        • 8.6.4.1.2.Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1.Market Trends and Opportunities
        • 8.6.4.2.2.Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1.Market Trends and Opportunities
        • 8.6.4.3.2.Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1.Market Trends and Opportunities
        • 8.6.4.4.2.Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1.Market Trends and Opportunities
        • 8.6.4.5.2.Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1.Market Trends and Opportunities
        • 8.6.4.6.2.Growth Prospects
      • 8.6.4.7. Others
        • 8.6.4.7.1.Market Trends and Opportunities
        • 8.6.4.7.2.Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. LKC Technologies
  • 10.2. Eye Patient
  • 10.3. ICR
  • 10.4. WellFirst Health
  • 10.5. Neurosoft
  • 10.6. Roland Consult
  • 10.7. Aetna
  • 10.8. USF Health
  • 10.9. Medico Electrodes